OPEN ACCESS ARTICLE – Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

Journal Name: Mini-Reviews in Medicinal Chemistry

Author(s): Voon Yee-Lin*, Wong Pooi-Fong , Alan Khoo Soo-Beng

 

 

 

 

Graphical Abstract:

 

Abstract:

Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer of multifactorial etiologies that is highly prevalent among men in the population of Southern China and Southeast Asia. NPC has claimed many thousands of lives worldwide; but the low awareness of NPC remains a hindrance in early diagnosis and prevention of the disease. NPC is highly responsive to radiotherapy and chemotherapy, but radiocurable NPC is still dependent on concurrent treatment of megavoltage radiotherapy with chemotherapy. Despite a significant reduction in loco-regional and distant metastases, radiotherapy alone has failed to provide a significant improvement in the overall survival rate of NPC, compared to chemotherapy. In addition, chemo-resistance persists as the major challenge in the management of metastatic NPC although the survival rate of advanced metastatic NPC has significantly improved with the administration of chemotherapy adjunctive to radiotherapy. In this regard, targeted molecular therapy could be explored for the discovery of alternative NPC therapies. Nutlin-3, a small molecule inhibitor that specifically targets p53-Mdm2 interaction offers new therapeutic opportunities by enhancing cancer cell growth arrest and apoptosis through the restoration of the p53-mediated tumor suppression pathway while producing minimal cytotoxicity and side effects. This review discusses the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment.

 

READ MORE HERE: http://www.eurekaselect.com/154246 

EDITOR’S CHOICE – Stereotactic Body Radiation Therapy in Head and Neck Squamous Cell Carcinoma – Current Cancer Therapy Reviews

Journal: Current Cancer Therapy Reviews

Author(s): Rashi Garg, Omar Mahmoud

Abstract:

Background: Stereotactic body radiotherapy (SBRT) or radiosurgery has emerged as a viable highly precise technique that delivers a hypofractionated radiotherapy regimen with a high biologic effective dose. In addition to patient convenience, this dose is thought to provide acceptable local control while keeping toxicity to a minimum due to the typical small target size. The aims of this paper are to review recent outcomes with the application of SBRT in the management of head and neck cancer.

Methods: Research and online content related to head and neck cancer SBRT were reviewed focusing on dose fractionation schedules, incorporation of systemic therapy and long term toxicity.

Results: SBRT technique provided convenient precise approach in the management of primary as well as recurrent head and neck cancer with adequate local control rates and tolerable long term toxicity profile.

Conclusion: The use of stereotactic body radiotherapy is still evolving and multiple studies are needed to optimize the dose fractionation of SBRT and its integration with systemic therapy.

Read more here: http://www.eurekaselect.com/159256/article

%d bloggers like this: